Global Multiple Sclerosis Treatment Market Report and Forecast 2024-2032

Global Multiple Sclerosis Treatment Market Outlook

The global multiple sclerosis treatment market size is driven by the rising prevalence of multiple sclerosis. The market attained a value of USD 27.44 billion in 2023. The market is further expected to grow at a CAGR of 4.3% during the forecast period of 2024-2032 to attain a value of USD 40.08 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Multiple Sclerosis Insights: Types, Causes, Symptoms, and Diagnosis

Multiple sclerosis is an autoimmune disorder in which the body’s immune system begins to attack its healthy cells. In this disorder, the cells of the myelin sheath surrounding the brain and the spinal cord are damaged by the immune system leading to impaired nerve signals from the brain to the other organs of the body.             

Depending on the onset and the severity, there are four types of multiple sclerosis, that are clinically isolated syndrome, relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, and secondary progressive multiple sclerosis.

The exact cause of this disease is still unclear and is under research, however, it is set to be triggered by the associated bacterial or viral infections, certain kinds of genetic mutations or some environmental factors.

Optic neuritis or other vision problems is the first noticeable symptom of multiple sclerosis. Muscle spasms, irregular coordination, muscle weakness, numbness, fatigue, and changes in gait are some of the common symptoms of this disorder.

The early and accurate diagnosis of multiple sclerosis is difficult as the symptoms of this disease are like other neurological disorders. However, blood tests, imaging tests and MRI scans are the exploratory tests used to diagnose multiple sclerosis. The confirmatory tests evoked potential tests and spinal taps are further done to ensure the prevalence of multiple sclerosis.

Multiple sclerosis is more prevalent in women as compared to men due to the differences in the immune system, lifestyle, and other genetic factors.

The multiple sclerosis treatment market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Indication Type

• Clinically Isolated Syndrome (CIS)

• Relapse-remitting MS (RRMS)

• Primary Progressive MS (PPMS)

• Secondary Progressive MS (SPMS)

Market Breakup by Diagnosis Method

• Blood and Imaging Tests

• Spinal Tap (Lumbar Puncture)

• Magnetic Resonance Imaging

• Evoked Potential Tests

• Others

Market Breakup by Treatment Method

• Corticosteroids

• Plasma Exchange (Plasmapheresis)

• Injectable Treatments
  • Interferon Beta Medications
  • Glatiramer Acetate (Glatopa)
• Oral Treatments
  • Fingolimod (Gilenya)
  • Dimethyl fumarate (Tecfidera)
  • Siponimod (Mayzent)
• Infusion Treatments
  • Ocrelizumab (Ocrevus)
  • Natalizumab (Tysabri)
  • Alemtuzumab (Campath, Lemtrada)

Market Breakup by End Users

• Hospitals

• Specialty Clinics

• Homecare

• Others

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The growth of the multiple sclerosis treatment market is driven by the rising prevalence and incidence of multiple sclerosis disease. By 2030, nearly 5 million subjects are expected to suffer from different types of multiple sclerosis.

The market is further driven by the rising focus of the key players on discovering novel products. For example, many key companies such as Biogen, Novartis, Bristol Myers Squibb Company, and many more are developing new drugs for the treatment of multiple sclerosis.

Besides, the heavy investments by the key players in the research and developmental activities are also expected to benefit the market. Big pharmaceutical companies aim to target as many multiple sclerosis indications as possible to attract a wide array of customers.

North America to Account for the Largest Share

North America is anticipated to hold the largest share of the multiple sclerosis treatment market during the forecast period owing to the increasing demand for the multiple sclerosis therapeutics, advanced healthcare infrastructure, rising awareness and favourable government policies for the treatment.

Furthermore, the presence of the significant key players, Pfizer, Bayer, Novartis, and the higher prevalence of multiple sclerosis in this region, has attributed to the growth of the North American market during the forecast period.

Therapeutic Landscape

There is no approved treatment regimen for the management of multiple sclerosis. However, the progression of the disease is controlled by the adoption of multiple treatment strategies.

Different Therapeutic Interventions in the Multiple Sclerosis Treatment Market

Firstly, healthcare professionals aim for the treatment of the symptoms. The symptomatic therapies target muscle spasticity, ataxia, pain, impaired movements, and bladder control.

The management of acute exacerbations is generally treated with the incorporation of Intravenous Immunoglobin, Corticosteroids, and plasma exchange or Plasmapheresis. Corticosteroids such as Prednisolone are most used for reducing nerve inflammation. In case of steroids failure, Plasmapheresis is wedded to manage the moderate to severe symptoms.

The major area of research and innovation spins around the treatment with disease-altering therapies. These treatment strategies can minimise the relapse frequencies and slow down the accumulation of physical disability. At present, there are approximately twelve disease-altering therapies approved for the management of the relapsing types of multiple sclerosis. These therapeutic interventions can be delivered orally, subcutaneously, and intravenously.

Ocrelizumab is one of the approved disease-modifying intravenous infusions used for treating primary progressive and relapse-remitting multiple sclerosis. Interferon beta medications are a set of injectable treatments to provide immediate multiple sclerosis symptomatic relief. The oral treatments for multiple sclerosis include Fingolimod, Teriflunomide and Dimethyl Fumarate.

Other medications, such as muscle relaxants and physical therapies, also assist in the alleviation of the symptoms of multiple sclerosis.

Clinical Trials Landscape

There is the availability of few disease-modifying therapies, henceforth there is the need for clinical trials for the discovery of novel therapeutic agents. Clinical studies are essential to assess the safety, efficacy, tolerability, and pharmacokinetics of pipeline products.

Emerging Therapies Aiding the Multiple Sclerosis Treatment Market Growth

A novel drug, ADS-5102, a formulation of amantadine, is under clinical studies. The drug has been found beneficial in the treatment of impaired movements in progressive multiple sclerosis. 

The Food and Drug Administration has recently approved a new oral drug, Ponvory, for the management of multiple sclerosis. During the clinical trials, the drug has reduced brain lesions and relapses by 30 per cent, hence being found effective in treating multiple sclerosis.

Emerging therapies such as BTK (Bruton’s Tyrosine Kinase) inhibitors are under evaluation for analysing their therapeutic effect and adverse effects. This acts by modulating B cells in the central nervous system.

Stem cell transplantation is another potent therapy found effective in the management of this disease. In this therapy, the destroyed immune system of multiple sclerosis patients is replaced by healthy stem cells. This therapy is still under investigation, and once approved can create plausible therapeutic prospects.

The ongoing research and developmental activities have shown promising benefits and opportunities and are anticipated to fuel the market growth during the forecast period.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the multiple sclerosis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Opexa Therapeutics, Inc.

• Bayer AG

• Teva Pharmaceutical Industries Ltd.

• Sanofi S.A.

• Actelion Pharmaceuticals Ltd.

• GSK plc

• Novartis AG

• Johnson & Johnson

• AstraZeneca plc

• Merck KGaA

• Abbott Laboratories

Key Highlights of the Report